Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatmentHilma J. van der Horst, Tuna Mutis, Ida H. Hiemstra et al.|Blood Cancer Journal|2021Cited by 95
Supplementary Data from Large B-cell Lymphomas of Immune-Privileged Sites Relapse via Parallel Clonal Evolution from a Common Progenitor B CellG. Tjitske Los-de Vries, Margaretha G.M. Roemer|Unknown|2023Cited by 0
Supplementary Data from Large B-cell Lymphomas of Immune-Privileged Sites Relapse via Parallel Clonal Evolution from a Common Progenitor B CellG. Tjitske Los-de Vries, Margaretha G.M. Roemer|Unknown|2023Cited by 0
Supplementary Data from Large B-cell Lymphomas of Immune-Privileged Sites Relapse via Parallel Clonal Evolution from a Common Progenitor B CellG. Tjitske Los-de Vries, Margaretha G.M. Roemer|Unknown|2025Cited by 0